These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 14613998)

  • 41. Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours.
    Schöffski P; Breidenbach I; Krauter J; Bolte O; Stadler M; Ganser A; Wilhelm-Ogunbiyi K; Lentzen H
    Eur J Cancer; 2005 Jul; 41(10):1431-8. PubMed ID: 15913988
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase I and pharmacokinetic study of BAY59: a novel taxane.
    Ramnath N; Hamm J; Schwartz G; Holden S; Eckhardt SG; Vredenburg MR; Bernacki RJ; Lathia C; Kanter P; Creaven PJ
    Oncology; 2004; 67(2):123-9. PubMed ID: 15539916
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
    Cohen SJ; Leichman CG; Yeslow G; Beard M; Proefrock A; Roedig B; Damle B; Letrent SP; DeCillis AP; Meropol NJ
    Clin Cancer Res; 2002 Jul; 8(7):2116-22. PubMed ID: 12114411
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
    Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
    Chow LQ; Jonker DI; Dy GK; Nicholas G; Fortin C; Patricia D; Adjei AA; Belani CP; Gupta A; Park JS; Zhang S; Sbar EI; Laurie SA
    Cancer Chemother Pharmacol; 2013 May; 71(5):1273-85. PubMed ID: 23468081
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
    Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors.
    Ramnath N; Schwartz GN; Smith P; Bong D; Kanter P; Berdzik J; Creaven PJ
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):227-30. PubMed ID: 12655441
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.
    Abraham J; Agrawal M; Bakke S; Rutt A; Edgerly M; Balis FM; Widemann B; Davis L; Damle B; Sonnichsen D; Lebwohl D; Bates S; Kotz H; Fojo T
    J Clin Oncol; 2003 May; 21(9):1866-73. PubMed ID: 12721265
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.
    Plummer R; Ghielmini M; Calvert P; Voi M; Renard J; Gallant G; Gupta E; Calvert H; Sessa C
    Clin Cancer Res; 2002 Sep; 8(9):2788-97. PubMed ID: 12231518
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
    Ibrahim NK; Desai N; Legha S; Soon-Shiong P; Theriault RL; Rivera E; Esmaeli B; Ring SE; Bedikian A; Hortobagyi GN; Ellerhorst JA
    Clin Cancer Res; 2002 May; 8(5):1038-44. PubMed ID: 12006516
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer.
    Cura JE; Blanzaco DP; Brisson C; Cura MA; Cabrol R; Larrateguy L; Mendez C; Sechi JC; Silveira JS; Theiller E; de Roodt AR; Vidal JC
    Clin Cancer Res; 2002 Apr; 8(4):1033-41. PubMed ID: 11948110
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors.
    Pitot HC; Reid JM; Sloan JA; Ames MM; Adjei AA; Rubin J; Bagniewski PG; Atherton P; Rayson D; Goldberg RM; Erlichman C
    Clin Cancer Res; 2002 Mar; 8(3):712-7. PubMed ID: 11895900
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
    Fujisaka Y; Yamada Y; Yamamoto N; Horiike A; Tamura T
    Jpn J Clin Oncol; 2010 Aug; 40(8):732-8. PubMed ID: 20430774
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
    Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
    Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.
    Gelderblom H; Salazar R; Verweij J; Pentheroudakis G; de Jonge MJ; Devlin M; van Hooije C; Seguy F; Obach R; Pruñonosa J; Principe P; Twelves C
    Clin Cancer Res; 2003 Sep; 9(11):4101-7. PubMed ID: 14519632
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks.
    Minami H; Fujii H; Igarashi T; Itoh K; Tamanoi K; Oguma T; Sasaki Y
    Clin Cancer Res; 2001 Oct; 7(10):3056-64. PubMed ID: 11595695
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor.
    Plummer R; Rees C; Hughes A; Beale P; Highley M; Trigo J; Gokul S; Judson I; Calvert H; Jackman A; Mitchell F; Smith R; Douglass E
    Clin Cancer Res; 2003 Apr; 9(4):1313-22. PubMed ID: 12684399
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase I trial of weekly paclitaxel, 13- cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies.
    Thalasila A; Poplin E; Shih J; Dvorzhinski D; Capanna T; Doyle-Lindrud S; Beers S; Goodin S; Rubin E; DiPaola RS
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):119-24. PubMed ID: 12768320
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients.
    Grem JL; Harold N; Keith B; Chen AP; Kao V; Takimoto CH; Hamilton JM; Pang J; Pace M; Jasser GB; Quinn MG; Monahan BP
    Clin Cancer Res; 2002 Jul; 8(7):2149-56. PubMed ID: 12114415
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel.
    Muindi JR; Peng Y; Potter DM; Hershberger PA; Tauch JS; Capozzoli MJ; Egorin MJ; Johnson CS; Trump DL
    Clin Pharmacol Ther; 2002 Dec; 72(6):648-59. PubMed ID: 12496746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.